✦ LIBER ✦

Adriamycin plus alkylating agents in the treatment of metastatic breast cancer

✍ Scribed by Jacob J. Lokich; Arthur T. Skarin; Robert J. Mayer; I. ÀIg Cr Henderson; Ronald H. Blum; Emil Frei III

Publisher: John Wiley and Sons
Year: 1977
Tongue: English
Weight: 391 KB
Volume: 40
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197712)40:6<2801::aid-cncr2820400608>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of mitoxantrone plus cyclophosph

The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer

✍ Werner R. Bezwoda; Charles Hesdorffer 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB 👁 1 views

Adriamycin and 1-(2-Chlorethyl)-3-Cycloh

Adriamycin and 1-(2-Chlorethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in the treatment of metastatic breast cancer

✍ William C. Waterfield; Charles K. Tashima; Gabriel N. Hortobagyi; George R. Blum 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

Cyproterone acetate in the treatment of

Cyproterone acetate in the treatment of metastatic cancer of the male breast

✍ Massimo Lopez 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

Etoposide in the management of metastati

Etoposide in the management of metastatic breast cancer

✍ George W. Sledge Jr 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

A dose-response evaluation of androgens

A dose-response evaluation of androgens in the treatment of metastatic breast cancer

✍ Robert W. Talley; Carleton R. Haines; M. Nancy Waters; Ira S. Goldenberg; Kennet 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

Adriamycin in combination for the treatm

Adriamycin in combination for the treatment of breast cancer. A southwest oncology group study

✍ Dr. B. Tranum; B. Hoogstraten; A. Kennedy; C. B. Vaughn; B. Samal; T. Thigpen; S 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c